Patent: 7,439,230
✉ Email this page to a colleague
Summary for Patent: 7,439,230
| Title: | Methods of treatment using CTLA4 mutant molecules |
| Abstract: | The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule. |
| Inventor(s): | Peach; Robert J. (San Diego, CA), Naemura; Joseph R. (Bellevue, WA), Linsley; Peter S. (Seattle, WA), Bajorath; Jurgen (Lynwood, WA) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 10/980,742 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,439,230
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2020-05-26 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2020-05-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
